Stocks · News reference
Gilead Sciences announced it will present new clinical data and real-world evidence from its HIV research programs at the upcoming International Congress on Drug Therapy in HIV Infection.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gilead Sciences reported positive results from its Phase 3 IDEAL study, showing that a majority of patients with Primary Biliary Cholangitis (PBC) treated with Livdelzi (seladelpar) achieved alkaline phosphatase (ALP) normalization.
Maxim Group has increased its price target for Gilead Sciences (GILD) from $165 to $200.
Gilead Sciences increased its quarterly dividend by 3.8% to $0.82, marking the 11th consecutive year of dividend increases. The company's strong HIV franchise generated 18% higher sales year-over-year, while its oncology expansion shows promise with Trodelvy reporting 42% sales growth. With a low payout ratio of 29.8%, Gilead has ample room to sustain dividend growth and fund $32 billion in research projects through 2030.
Gilead Sciences and its subsidiary Kite announced that they will present 23 clinical data updates at the 68th American Society of Hematology (ASH) Annual Meeting.
DZ Bank has increased its price target for Gilead Sciences, moving it from $167 to $191.